News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      Yohimbe (Herb/Suppl)

      Brand and Other Names:aphrodien, corynanthe yohimbi, more...corynine, johimbi, pausinystalia yohimbe, quebrachine
      • Print

      Suggested Dosing

      Sexual Dysfunction

      15-30 mg PO daily

      Bark tincture: 5-10 gtt PO TID

      Yohimbe bark: Potential for side effects

      Numerous regimens available, follow mfct recommendations

      Next:

      Suggested Uses

      Erectile dysfunction, sexual dysfunction (male or female), sexual dysfunction (SSRI-induced)

      Efficacy

      Possibly effective for impotence

      Previous
      Next:

      Interactions

      Interaction Checker

      and Yohimbe

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (0)

                  Serious - Use Alternative (58)

                  • alfuzosin

                    yohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.

                  • amitriptyline

                    yohimbe, amitriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • amoxapine

                    yohimbe, amoxapine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • asenapine

                    yohimbe increases effects of asenapine by pharmacodynamic synergism. Contraindicated.

                  • benzphetamine

                    yohimbe, benzphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • chlorpromazine

                    yohimbe decreases effects of chlorpromazine by pharmacodynamic antagonism. Contraindicated.

                  • clomipramine

                    yohimbe, clomipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • clonidine

                    yohimbe decreases effects of clonidine by pharmacodynamic antagonism. Contraindicated.

                  • desipramine

                    yohimbe, desipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • dexfenfluramine

                    yohimbe, dexfenfluramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • dexmethylphenidate

                    yohimbe, dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • dextroamphetamine

                    yohimbe, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • diethylpropion

                    yohimbe, diethylpropion. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • dobutamine

                    yohimbe, dobutamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • dopamine

                    yohimbe, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • dosulepin

                    yohimbe, dosulepin. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • doxazosin

                    yohimbe increases effects of doxazosin by pharmacodynamic synergism. Contraindicated.

                  • doxepin

                    yohimbe, doxepin. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • ephedrine

                    yohimbe, ephedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • epinephrine

                    yohimbe, epinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • fenfluramine

                    yohimbe, fenfluramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • fluphenazine

                    yohimbe decreases effects of fluphenazine by pharmacodynamic antagonism. Contraindicated.

                  • imipramine

                    yohimbe, imipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • isoproterenol

                    yohimbe, isoproterenol. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • lisdexamfetamine

                    yohimbe, lisdexamfetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • lofepramine

                    yohimbe, lofepramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • maprotiline

                    yohimbe, maprotiline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • methamphetamine

                    yohimbe, methamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • methylenedioxymethamphetamine

                    yohimbe, methylenedioxymethamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • methylphenidate

                    yohimbe, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • midodrine

                    yohimbe, midodrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • moxisylyte

                    yohimbe increases effects of moxisylyte by pharmacodynamic synergism. Contraindicated.

                  • norepinephrine

                    yohimbe, norepinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • nortriptyline

                    yohimbe, nortriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • perphenazine

                    yohimbe decreases effects of perphenazine by pharmacodynamic antagonism. Contraindicated.

                  • phendimetrazine

                    yohimbe, phendimetrazine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • phenoxybenzamine

                    yohimbe increases effects of phenoxybenzamine by pharmacodynamic synergism. Contraindicated.

                  • phentermine

                    yohimbe, phentermine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • phentolamine

                    yohimbe increases effects of phentolamine by pharmacodynamic synergism. Contraindicated.

                  • phenylephrine

                    yohimbe, phenylephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • phenylephrine PO

                    yohimbe, phenylephrine PO. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • prazosin

                    yohimbe increases effects of prazosin by pharmacodynamic synergism. Contraindicated.

                  • prochlorperazine

                    yohimbe decreases effects of prochlorperazine by pharmacodynamic antagonism. Contraindicated.

                  • promazine

                    yohimbe decreases effects of promazine by pharmacodynamic antagonism. Contraindicated.

                  • promethazine

                    yohimbe decreases effects of promethazine by pharmacodynamic antagonism. Contraindicated.

                  • propylhexedrine

                    yohimbe, propylhexedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • protriptyline

                    yohimbe, protriptyline. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • serdexmethylphenidate/dexmethylphenidate

                    yohimbe, serdexmethylphenidate/dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • silodosin

                    yohimbe increases effects of silodosin by pharmacodynamic synergism. Contraindicated.

                  • terazosin

                    yohimbe increases effects of terazosin by pharmacodynamic synergism. Contraindicated.

                  • thioridazine

                    yohimbe decreases effects of thioridazine by pharmacodynamic antagonism. Contraindicated.

                  • trazodone

                    yohimbe, trazodone. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • trifluoperazine

                    yohimbe decreases effects of trifluoperazine by pharmacodynamic antagonism. Contraindicated.

                  • trimipramine

                    yohimbe, trimipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.

                  • tyramine

                    yohimbe, tyramine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode. Tyramine containing foods include cheese, red wine, caviar, herring, canned figs, fermented meats, fava beans, yeast extracts, miso, avocado.

                  • xylometazoline

                    yohimbe, xylometazoline. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • yohimbine

                    yohimbe, yohimbine. Mechanism: pharmacodynamic synergism. Contraindicated. Risk of acute hypertensive episode.

                  • zotepine

                    yohimbe increases effects of zotepine by pharmacodynamic synergism. Contraindicated.

                  Monitor Closely (5)

                  • isocarboxazid

                    yohimbe increases effects of isocarboxazid by pharmacodynamic synergism. Use Caution/Monitor.

                  • linezolid

                    yohimbe increases effects of linezolid by pharmacodynamic synergism. Use Caution/Monitor.

                  • phenelzine

                    yohimbe increases effects of phenelzine by pharmacodynamic synergism. Use Caution/Monitor.

                  • procarbazine

                    yohimbe increases effects of procarbazine by pharmacodynamic synergism. Use Caution/Monitor.

                  • tranylcypromine

                    yohimbe increases effects of tranylcypromine by pharmacodynamic synergism. Use Caution/Monitor.

                  Minor (16)

                  • acebutolol

                    acebutolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • atenolol

                    atenolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • betaxolol

                    betaxolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • bisoprolol

                    bisoprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • carvedilol

                    carvedilol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • celiprolol

                    celiprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • esmolol

                    esmolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • labetalol

                    labetalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • metoprolol

                    metoprolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • nadolol

                    nadolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • nebivolol

                    nebivolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • penbutolol

                    penbutolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • pindolol

                    pindolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • propranolol

                    propranolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • sotalol

                    sotalol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • timolol

                    timolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  Anxiety, cardiac coduction disturbances, cardiac failure, dizziness, excitation, fluid retention, gastric intolerance, headache, hypertension, hypotension, insomnia, irritability, nausea/vomiting, paralysis, respiratory depression, salivation, sinusitis, tachycardia, tremor, urinary frequency

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Angina, anxiety, BPH, concomitant MAO inhibitors, concomitant sympathomimetic drugs, depression, diabetes mellitus, heart disease, hypertension, hypotension, kidney disease, liver disease, post-traumatic stress disorder, prostate inflammation, tyramine-containing foods

                  Cautions

                  Schizophrenia

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: unsafe

                  Lactation: avoid use

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Metabolism: N/A

                  Excretion: N/A

                  Mechanism of Action

                  Yohimbine is an alpha-2-adrenergic blocker

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                  Find Us On
                  About
                  About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                  Membership
                  Become a Member About You Professional Information Newsletters & Alerts Market Research
                  App
                  Medscape
                  WebMD Network
                  Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
                  Editions
                  English Deutsch Español Français Português UK
                  All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.